

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

ESOPHAGOGASTRIC DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

Venue: Rossetti Room, Delta Chelsea Hotel, Toronto

Date: Saturday, April 28th, 2012

Time: 10:30 to 12:00 hrs

Chairs: Dr. Rebecca Wong & Dr. Christian Kollmansberger

10:30	WELCOME AND INTRODUCTION	DR. R. WONG & DR. C. KOLLMANSBERGER
10:30 – 10:35	COMPLETED TRIALS	
	ES.2 (TROG 03.01): A RANDOMISED PHASE III STUDY IN ADVANCED OESOPHAGEAL CANCER TO COMPARE QUALITY OF LIFE AND PALLIATION OF DYSPHAGIA IN PATIENTS TREATED WITH RT VS CRT	DR. R. WONG
10:35 – 11:20	APPROVED TRIALS	
	GA.1 (TOP GEAR): A RANDOMISED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER DRS. C. KOLLMANSBERGER, G. DARLING, C. SWALLOW, J. RINGASH AND G. LIU	
11:20 – 11:55	TRIAL PROPOSALS/CONCEPTS IN DEVELOPMENT	
	INTEGRATE: A RANDOMISED PHASE II DOUBLE-BLIND STUDY OF REGORAFENIB OR PLACEBO IN REFRACTORY ADVANCED OESOPHAGO-GASTRIC CANCER (AOGC)	DR. D. JONKER
	NEOADJUVANT CHEMOTHERAPY VS NEOADJUVANT CHEMORADIATION IN PATIENTS WITH SURGICALLY RESECTABLE ESOPHAGEAL CARCINOMA – A PILOT RANDOMIZED STUDY	DR. G. BUDUHAN
11:55 – 12:00	INTERGROUP TASK FORCE UPDATE	
12:00	CLOSING REMARKS	